High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs

NCT01965275 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Self Efficacy
Drug Toxicity

Interventions

DRUG: Erlotinib or Gefitinib

Sponsor

Anhui Medical University